Logo-aim
Arch Iran Med. 2021;24: 881-886.
doi: 10.34172/aim.2021.132
  Abstract View: 352
  PDF Download: 241

Original Article

Role of Tumor Subtypes in Response to Neoadjuvant Chemotherapy in Non-metastatic Breast Cancer

Negar Mashoori 1* ORCID logo, Ramesh Omranipour 2, Abdolali Assarian 3

1 Tehran University of Medical Sciences, Tehran, Iran
2 Breast Disease Research Center, Department of Surgical Oncology, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Breast Surgery Unit, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: *Corresponding Author: Negar Mashoori, MD; Cancer Institute, Imam Khomeini Hospital, Gharib Blvd., Tehran, Iran. Tel:+98-912-5857039; Fax:+98-21- 66581657; Email: , Email: n.mashoori@gmail.com

Abstract

Background: Neoadjuvant chemotherapy (NAC) is an integral part of breast cancer treatment. Determination of the factors that can distinguish patients who will have best response to NAC is invaluable. In this study, we aimed to elucidate the factors influencing patient response to NAC.

Methods: We retrospectively collected data of female patients with non-metastatic breast cancer that had received NAC followed by surgery, admitted to Imam Khomeini hospital between 2015–2019. We investigated the association between various tumor and patients’ characteristics with pathologic complete response (PCR).

Results: Overall data of 205 female patients were collected. PCR was observed in 27.6% of cases. PCR rate in luminal A, luminal B, HER2 enriched, and TNB tumors was reported in 11.1%, 30.2%, 35.7%, and 36.4% of patients respectively (P=0.27). In patients with luminal B tumors, PCR was more prevalent in patients with positive HER2 only (P=0.006). In our study factors which was significantly associated with PCR were: tumor grade, progesterone receptor (PR) status, and HER2 status. In the multiple regression model, positive PR in the tumor lowered the odds of pathologic response 3.6 times (P=0.004).

Conclusion: In our study, tumor grade, PR status, and HER2 status was associated with response to NAC. PCR was more prevalent in non-luminal tumors; however, PCR rate in luminal B patients-especially those with HER2 positive status- was slightly less than non-luminals.


Keywords: Breast cancer, Neoadjuvant chemotherapy, Pathologic complete response, Tumor subtype

Cite this article as: Mashoori N, Omranipour R, Assarian A. Role of tumor subtypes in response to neoadjuvant chemotherapy in non-metastatic breast cancer. Arch Iran Med. 2021;24(12):881-886. doi: 10.34172/aim.2021.132
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 353

Your browser does not support the canvas element.


PDF Download: 241

Your browser does not support the canvas element.

Submitted: 03 Jun 2020
Revision: 22 Apr 2021
Accepted: 05 May 2021
ePublished: 01 Dec 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)